***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic , generally well tolerated , and effective against HPV-16 or HPV-18 infections , and associated precancerous lesions in an event-triggered interim analysis of the phase III r and omised , double-blind , controlled PApilloma TRIal against Cancer In young Adults ( PATRICIA ) . We now assess the vaccine efficacy in the final event-driven analysis . METHODS Women ( 15 - 25 years ) were vaccinated at months 0 , 1 , and 6 . Analyses were done in the according-to- protocol cohort for efficacy ( ATP-E ; vaccine , n=8093 ; control , n=8069 ) , total vaccinated cohort ( TVC , included all women receiving at least one vaccine dose , regardless of their baseline HPV status ; represents the general population , including those who are sexually active ; vaccine , n=9319 ; control , n=9325 ) , and TVC-naive ( no evidence of oncogenic HPV infection at baseline ; represents women before sexual debut ; vaccine , n=5822 ; control , n=5819 ) . The primary endpoint was to assess vaccine efficacy against cervical intraepithelial neoplasia 2 + ( CIN2 + ) that was associated with HPV-16 or HPV-18 in women who were seronegative at baseline , and DNA negative at baseline and month 6 for the corresponding type ( ATP-E ) . This trial is registered with Clinical Trials.gov , number NCT00122681 . FINDINGS Mean follow-up was 34.9 months ( SD 6.4 ) after the third dose . Vaccine efficacy against CIN2 + associated with HPV-16/18 was 92.9 % ( 96.1 % CI 79.9 - 98.3 ) in the primary analysis and 98.1 % ( 88.4 - 100 ) in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types ( ATP-E cohort ) . Vaccine efficacy against CIN2 + irrespective of HPV DNA in lesions was 30.4 % ( 16.4 - 42.1 ) in the TVC and 70.2 % ( 54.7 - 80.9 ) in the TVC-naive . Corresponding values against CIN3 + were 33.4 % ( 9.1 - 51.5 ) in the TVC and 87.0 % ( 54.9 - 97.7 ) in the TVC-naive . Vaccine efficacy against CIN2 + associated with 12 non-vaccine oncogenic types was 54.0 % ( 34.0 - 68.4 ; ATP-E ) . Individual cross-protection against CIN2 + associated with HPV-31 , HPV-33 , and HPV-45 was seen in the TVC . INTERPRETATION The HPV-16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2 + associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes . FUNDING GlaxoSmithKline Biologicals BACKGROUND This phase III trial was to compare 5-fluorouracil ( 5-FU ) , adriamycin , and polyadenylic-polyuridylic acid ( poly A : U ) against 5-fluorouracil plus adriamycin ( FA ) for operable gastric cancer . PATIENTS AND METHODS From 1984 to 1989 , patients who had D(2 - 3 ) curative resection were r and omly assigned to receive chemotherapy or chemoimmunotherapy . Chemotherapy consisted of 12 mg/kg 5-FU every week for 18 months and 40 mg/m2 adriamycin every 3 weeks for 12 cycles . Chemoimmunotherapy consisted of FA plus 100 mg of poly A : U weekly for six cycles and was followed 6 months later by six weekly 50-mg booster injections . RESULTS A total of 292 patients were enrolled . After excluding 12 ineligible patients , 142 and 138 patients were allocated to each treatment . Patients were balanced with prognostic variables : age , sex , tumor location , differentiation , degree of tumor invasion ( T2-T4a ) , and lymph node status ( N0-N2 ) . During the 15-year follow-up , chemoimmunotherapy significantly prolonged overall ( P = 0.013 ) and recurrence-free ( P = 0.005 ) survivals compared with chemotherapy alone . The survival benefits were prominent in the subset of patients with T3/T4a , N2 , or stage III . Treatments were generally well tolerated in both arms . CONCLUSIONS These results indicate a survival advantage of chemoimmunotherapy with a regimen of FA and poly A : U in curatively resected gastric adenocarcinoma The toll‐like receptor ( TLR ) 7 agonist 852A , a small‐molecule imidazoquinoline , stimulates plasmacytoid dendritic cells to produce multiple cytokines . We conducted a Phase II study of 852A in patients with recurrent hematologic malignancies . The primary objective was assessing the activity of 852A administered subcutaneously twice weekly for 12 weeks . Secondary objectives were assessing the safety of  852A and its ability to activate the immune system with prolonged dosing . Patients with relapsed hematologic malignancies of any age with adequate organ function were eligible . Patients initiated dosing at 0.6 mg/m2 twice weekly and escalated by 0.2 mg/m2 after every two doses as tolerated to a target dose of 1.2 mg/m2 . Patients with responses or stable disease were eligible for additional cycles . Seventeen patients ( 15 males ) entered the study : 6 with AML , 5 ALL , 4 NHL , 1 Hodgkin 's lymphoma , and 1 multiple myeloma . The mean age was 41 years ( 12–71 years ) . The median number of prior chemotherapy regimens was 5 ( range = 1–14 ) . Thirteen patients completed all 24 injections . Grade 3‐4 toxicities included nausea , dyspnea , fever , myalgia , malaise , and cough . Responses included one complete response ( ALL ) , one partial response ( AML ) , two stable disease ( AML and NHL ) , and 9 progressive disease . This is the first in‐human hematologic malignancy trial of a subcutaneously ( SC ) delivered TLR7 agonist using a prolonged dosing schedule . 852A was safely administered up to 1.2 mg/m2 twice weekly with evidence of sustained tolerability and clinical activity in hematologic malignancies . Systemic TLR agonists for the treatment of hematologic malignancies warrant further study . Am . J. Hematol . 2012 . © 2012 Wiley Periodicals , 
    Output:
    
We show that targeting TLRs in cancer immunotherapy is a promising strategy for cancer therapy , and the specific TLR lig and s , either alone or combination , exhibit antitumor potential